Immune Monitoring Core

激活细胞免疫系统的疗法（免疫疗法）是发展最快的疗法之一。 癌症治疗领域的增长。测试新免疫疗法的临床试验的关键部分，例如 针对肿瘤抗原的疫苗，正在监测肿瘤特异性免疫反应，以验证我们是否 实际上靶向和激活特定的白细胞亚群，以及免疫激活是否 与临床结果相关。此外，正确解释这些免疫反应的结果 因此，需要进行免疫分析以找到优化免疫疗法的方法用于未来的临床试验。UT MD安德森 癌症中心最近在其南校区建立了一个免疫监测核心实验室（IMCL 作为其癌症免疫治疗计划扩展的一部分。这个核心实验室拥有许多 支持T细胞临床和临床前评估所需的关键技术和基础设施 ARC在癌症患者中的功能，包括血液和肿瘤的处理和储存，细胞培养工具， 体外刺激、流式细胞术和使用细胞因子和CTL测量抗原特异性T细胞功能 测定。我们还在开发新的和更敏感的T细胞检测技术， 推出了一种新的高灵敏度非放射性CTL检测方法。IMCL的目的是支持临床前 和临床方面的所有项目在这个PO 1赠款。在PO 1授予期间，IMCL将 通过协助血液和组织处理，与所有PO 1项目合作，并将帮助开发可持续发展 流式细胞术和细胞测定来表征pDC对抗肿瘤T细胞表型的作用， 功能我们的主要活动之一是在项目4的临床试验中进行免疫监测 其将测试TLR 7和TLR 8激动剂在gp 100和法师-3肽疫苗接种过程中在小鼠中的作用。 黑色素瘤患者。IMCL将处理所有外周血单核细胞样本和肿瘤活检 从这次试验开始，建立标本库，并在试验期间建立电子标本数据库。 临床试验（6个月至4.5年-Mpt/mo）。在第一年，我们将与项目4一起优化和验证 T细胞表型和功能测定，将用于资助期第5年，以监测抗原特异性 参加临床试验的患者的T细胞应答。所有免疫监测测量将 与生物统计学和数据管理核心（核心C）合作进行分析。

The development of therapies activating the cellular immune system (immunotherapy) is one of the fastest growing areas of cancer treatment. A critical part of clinical trials testing new immunotherapies, such as vaccines against tumor antigens, is monitoring tumor-specific immune responses to validate whether we are actually targeting and activating specific leukocyte subsets as intended, and whether immune activation correlates with clinical outcome. In addition, proper interpretation of the results of these immune response assays is needed to find ways of optimizing immunotherapies for future clinical trials. UT MD Anderson Cancer Center has recently established an immune monitoring core laboratory (IMCL) at its South Campus as part of the expansion of its immunotherapy program in cancer. This core laboratory houses a number of key technologies and infrastructure needed to support both clinical and pre-clinical assessment of T-cell and ARC function in cancer patients, including blood and tumor processing and storage, cell culture tools for in vitro stimulation, flow cytometry, and measurement of antigen-specific T-cell function using cytokine and CTL assays. We are also developing new and more sensitive T-cell assay technologies and have recently launched a new highly-sensitive non-radioactive CTL assay. The aim of the IMCL will be to support both preclinical and clinical aspects of all projects in this PO1 grant. Throughout the PO1 grant period, the IMCL will work with all the PO1 Projects by assisting in blood and tissue processing and will help develop multicolor flow cytometry and cellular assays to characterize the effects of pDC on anti-tumor T cell phenotype and function. One of our main activities will be to perform the immune monitoring in the clinical trial of Project 4 that will test the effects of TLR7 and TLR8 agonists during gplOO and MAGE-3 peptide vaccination in melanoma patients. The IMCL will process all peripheral blood mononuclear cell samples and tumor biopsies from this trial, establish a specimen storage bank, and develop an electronic specimen database during the clinical trial (Month 6 to Year 4.5 -Mpt/mo). In Year 1 we will work with Project 4 in optimizing and validating T-cell phenotypic and functional assays that will be used in Year 5 of the grant period to monitor the antigenspecific T cell responses in patients enrolled on the clinical trial. All immune monitoring measurements will be analyzed in collaboration with the Biostatistics and Data Management Core (Core C).